The neuroprotective effect of PPAR agonists have recently been proposed using neurological murine models and include anti-inflammatory effects, APP degradation, and Aβ inhibitory functions [41,42,43,44,45] The pharmacological modulation of PPARs by pioglitazone, rosiglitazone, ibuprofen, piroxicam, ciglitazone, and GW1929 has been shown to be neuroprotective in AD, ALS, MS, and PD models [46,47,48,49,50,51]. Here, APP is linked to Parkinson disease.